Company news
Inmed Pharmaceuticals Inc. (NASDAQ:INM) news
Inmed Pharmaceuticals Inc. news releases on 6ix. Latest, Nov 3, 2021: InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative…
Press releases — page 3
InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid
November 2, 2021
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids
October 12, 2021
InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa
September 29, 2021
InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update
September 23, 2021
InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids
September 12, 2021
InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids
June 28, 2021
InMed Pharmaceuticals Announces $12 Million Private Placement Priced At-the-Market under Nasdaq Rules
June 28, 2021
InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale Production
June 16, 2021
InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results
May 12, 2021
InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa
April 27, 2021
InMed Pharmaceuticals Announces Voluntary Delisting from TSX
April 26, 2021
InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™
April 25, 2021
InMed Announces Closing of US$4.5 Million Private Placement
February 15, 2021
InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results
February 10, 2021
InMed Announces US$4.5 Million Private Placement
February 4, 2021
InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
January 7, 2021
InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids
December 2, 2020
InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
November 24, 2020
InMed Announces Election of Directors
November 23, 2020
InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics
November 17, 2020
InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering
November 15, 2020
InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results
November 12, 2020
InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol "INM"
November 11, 2020